CD4 and myeloid sarcoma: A previous study shows that TNFAIP3 expression level is diminished in monocytes and CD4 + T cells of MS patients, suggesting TNFAIP3 plays a role in anti-inflammatory pathways, which might contribute to MS risk [46].